PubMed1987
The effects of a nitroglycerin transdermal therapeutic system (TTS NG 10 mg/24 h) 24 hours after application were evaluated by exercise left ventricular radionuclide cineangiography. 20 patients with ischemic heart disease were included in a double-blind, within patient, acute study comparing TTS NG to placebo. Were measured: exercise-test parameters and global (EF) and regional (rEF) ejection fractions at rest and during exercise. At maximum load, the double product rose from 18,680 +/- 4,118 with placebo to 21,538 +/- 3,988 with TTs NG (p less than 0.01) and ST-segment depression at same load decreased from 2.6 +/- 0.7 mm with placebo to 1.0 +/- 0.7 mm with TTS NG (p less than 0.001). Exercise EF increased from 0.57 +/- 0.15 with placebo to 0.63 +/- 0.12 with TTS NG (p less than 0.001) and was higher at exercise than at rest. Two hypokinetic territories improved during exercise with TTS NG: basal rEF increased to 0.45 +/- 0.07 with TTS NG versus 0.31 +/- 0.13 with placebo (p less than 0.01); anteroseptal rEF increased to 0.49 +/- 0.14 versus 0.43 +/- 0.14 with placebo (p 0.05); no significant improvement was observed in anterolateral and inferior territories were previous myocardial infarction occurred predominantly. These data demonstrate the 24 hours efficacy of this new galenic form of TTS NG in ischemic heart disease on exercise test parameters. TTS NG improving predominantly regional kinetics of ischemic but non infarcted territories and thus improving EF at exercise.
Administration, Cutaneous↗